A discordant lymphoma occurs where two distinct histologic subtypes coexist in at least two separate anatomic sites. Histological discordance is most commonly observed between the bone marrow and lymph nodes where typically aggressive lymphoma is found in a lymph node biopsy with indolent lymphoma in a bone marrow biopsy. While the diagnosis of discordance relied heavily on histopathology alone in the past, the availability of flow cytometry and molecular studies have aided the identification of this entity. The true prevalence and clinical ramifications of discordance remain controversial as available data are principally retrospective, and there is therefore little consensus to guide optimal management strategies. In this review, we examine the available literature on discordant lymphoma and its outcome and discuss current therapeutic approaches. Future studies in discordant lymphoma should ideally focus on large series of patients with adequate tissue samples and incorporate molecular analyses.
Introduction
Bone marrow involvement (BMI) at diagnosis is present in the majority of indolent B-cell lymphomas and in most studies, is reported to occur in approximately 10%-15% of diffuse large B-cell lymphoma (DLBCL) cases. 1, 2 It is an important clinical test and performed even when the likelihood of involvement is low as it may portend an inferior clinical outcome and impact therapy selection. 3 While, in most cases where BMI occurs, histology is concordant among involved sites, 'discordance' refers to those lymphoma cases where the histology is distinctly different between the BM and other sites of involvement. It is important to distinguish 'discordant' from 'composite' -the latter term refers to 'lymphomas in which two or more distinct areas of different histology can be appreciated in a single lymph node' as opposed to these findings in separate anatomic sites in the case of 'discordance'. 4, 5 Concordant and discordant clonality will also be discussed here, but histologic discordance does not mandate concordant clonality. In discussing 'discordant' lymphomas, it is also important to distinguish 'discordance' from 'transformation.' Transformed lymphomas are defined as indolent lymphoma cases that undergo histologic transformation into aggressive lymphoma (usually DLBCL) during the course of the disease. They include 'Richter's transformation or 'Richter' syndrome, which describes cases of chronic lymphocytic leukemia (CLL) that transform into DLBCL or Hodgkin lymphoma. 6, 7 There is a paucity of published experience on the biology, diagnosis, treatment, and outcome of discordant lymphomas, and data are mostly derived from single case reports and small retrospective studies. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Consequently, the incidence, clinical behavior, and optimal therapeutic approach to discordant lymphomas remain
For personal use only. on November 1, 2017. by guest www.bloodjournal.org From controversial with little overall consensus. In this review, we analyze the published literature on discordant non-Hodgkin lymphomas, with particular emphasis on diffuse large B-cell lymphomas (DLBCL). The review of the literature was performed by a search of the medical literature using the PubMed database at www.pubmed.gov.
Diagnosis of discordant lymphoma
The diagnosis of discordant lymphoma is based on histological appearances but is challenging for the pathologist as no minimal criteria to define discordance are rigorously established and/or uniformly used.
1, 18 Although morphology is the cornerstone of diagnosis, the immunophenotypic and molecular characteristics of the lymphoma subtype may be helpful in diagnosing discordance. While BMI of any histologic type has been found in an estimated 11-33% of patients with aggressive Bcell lymphomas, BMI with indolent NHL (discordance) has ranged from between 5-24% in the limited studies that have been performed (Table 1) . 1,2,4,19-22 Interestingly, in the post-rituximab era, the incidence of discordance is reported to be less and two recent analyses report indolent BMI with nodal DLBCL in 5% and 7% of cases -this may reflect a reduction in the widespread use of bilateral BM biopsies over time, and a resulting decreased detection of discordant disease. 2, 21 Additionally, the definition of discordance has become more refined with the availability of more sensitive methods for identifying lymphomatous involvement. Specifically, there are now improved immunohistochemical techniques as well as wider availability of flow cytometry and PCR to test for clonality of B-cells and this has resulted particularly in the easier identification of benign lymphoid aggregates. 
Impact of Discordance on Outcome
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The prognostic significance of discordant disease in the pre-rituximab era is limited by small sample sizes and the retrospective nature of the analyses. However, some studies have shown that patients with diffuse large B-cell lymphoma and concordant BMI have an inferior overall survival (OS) compared to those with discordant BMI, (who interestingly have survival rates similar to cases without lymphomatous BMI). 4, 19, 25 In addition, a decrease in OS has been observed when a greater proportion of large cells were present in the marrow infiltrate. 20, 26 Interestingly, patients with concordant histology had an inferior OS independent of the International prognostic index (IPI), while those with discordant BMI had no significant effect on survival even when accounting for IPI.
1
The data regarding the rate of relapse following initial therapy in the presence of discordant BMI are conflicting. In a small series of 13 patients with discordant BM histology, all documented recurrences were of the original large cell lymphoma, rather than relapsed indolent marrow disease. Six of seven of these relapses occurred within the first two years after diagnosis. 25 Conversely, others have reported that patients with discordant marrow histology have a higher rate of late relapse, with histology showing indolent disease in 7 of 10 relapsed patients. Over half the cases with disease progression occurred more than two years after diagnosis. 22 At this point in the pre-rituximab era of therapy, it was unclear whether a diagnosis of discordance truly implied a higher rate of relapse, and if the relapse involved the aggressive or the indolent clone.
In the post rituximab era, disparate outcomes of discordant and concordant involvement are similar to in the pre-rituximab era. In a recent retrospective analysis of patients with DLBCL receiving R-CHOP, those with concordant marrow involvement had a worse overall and progression free survival (PFS) than patients intriguing, it has been argued that this particular study is limited by the lack of correlation with full gene expression profiling. 27 Similarly, in the previously discussed analysis of 133 patients with DLBCL treated with R-CHOP, concordant but not discordant BMI also correlated with worse OS and PFS in a univariate analysis, not controlling for IPI. 24 A more recent study also showed that concordant BMI was predictive of worse OS and PFS independent of IPI score, while once again discordant BMI did not.
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In terms of patterns of relapsed disease in the post-rituximab era, there is a clearer pattern of relapse, which is predominantly of the aggressive large B-cell lymphoma rather than indolent disease. In 2011, Sehn et al. reported that the majority of patients with DLBCL having discordant marrow involvement with relapsed disease had progression of the aggressive lymphoma rather than the indolent lymphoma initially found in the marrow (92%; or 22 out of 24 patients), and in 88% of cases disease progression occurred in the first two years after diagnosis. 2 The above studies are summarized in Table 1 .
Discordant BMI in Indolent B-cell Lymphoma:
Concordant BMI has long been known to predict worse survival outcomes in patients with nodal follicular lymphoma, as it results in upgrading to an Ann Arbor stage of IV and thus a higher FLIPI score. 28 Concordant BMI has been estimated to occur in 40-70% of patients with follicular lymphoma. 29 In a study of discordant lymphomas reported in 1995, two patients with follicular lymphoma thought to have discordant lymphoma on BM biopsy, were found to have bcl-2 gene rearrangements, suggesting the presence of follicular lymphoma in the marrow rather than true discordance.
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Recently in a Norwegian series of 96 patients with follicular lymphoma, concordant BMI determined by immunoglobulin heavy and light chain gene rearrangement analysis predicted worse survival, even when present in the absence of histologically concordant BMI. 29 No cases of histologic discordance incidentally found on immunoglobulin chain rearrangement PCR were reported, suggesting that clonally unrelated disease in the marrow is uncommon in follicular lymphoma.
Similarly, in a series of 91 patients with follicular lymphoma in which BMI was determined both by histology as well as flow cytometry, no cases of discordant lymphomatous involvement were reported. 31 In a large series of 450 patients with NHL, including 345 cases with lymph node or other biopsy material available to view, only 6 patients with follicular lymphoma on an extramedullary biopsy specimen had DLBCL BMI by histology, and no other discordant histologies were described.
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In a recent British series of 345 patients with NHL for whom both lymph node and BM biopsy were available, only 8 patients with follicular lymphoma were found to have discordant marrow disease by histology, all of which were classified as Prevalence of histologic BMI was 90% for splenic MZL, 54% for nodal type, and 22% for extra-nodal MZL. In all these subtypes, when BMI was found, the marrow showed similar cytologic and immunophenotypic profiles to the original disease site, suggesting that discordant BM histology is infrequent in this subtype of NHL. 34 As expected, concordant BMI was significantly associated with more advanced Ann
Arbor stage, presence of B symptoms, presence of leukemic disease, higher number of nodal and extranodal sites, and higher IPI and age-adjusted IPI. Twenty-seven patients underwent repeat BM biopsy after diagnosis and three patients were then found to have discordant BM findings. Two patients with previously negative BM biopsies showed a shift to higher grade large B cell lymphoma 12 and 6 years after diagnosis, and one patient had a "myeloma" like infiltrate after receiving CHOP. 34 In another large series, only 3 patients with lymph node marginal zone lymphoma were found to have DLBCL on BM biopsy.
Another possible rare presentation is the presence of two types of indolent lymphomas diagnosed simultaneously from different sites. Indeed, some case reports have described the diagnosis of mantle cell lymphoma with marginal zone lymphoma, 35 or the association of MALT lymphoma with follicular lymphoma. 13, 14 In summary, discordant BMI in indolent lymphomas, has mostly been described for follicular lymphoma, and even here the frequency appears to be low, and mostly manifested as DLBCL on BM biopsy, probably indicative of transformed disease.
Role of PET imaging as non-invasive evaluation:
For
A number of studies have suggested that FDG PET can predict BMI with high sensitivity in aggressive non-Hodgkin lymphomas. [36] [37] [38] [39] [40] In contrast, the literature describing BMI in follicular lymphoma is more limited, and suggests that PET is less sensitive to detect concordant BMI by follicular lymphoma (FL). 41, 42 In one study only 13 of 24 patients with biopsy-proven BMI by FL had involvement by PET evaluation, with PET findings suspicious for BMI being defined as diffuse FDG uptake in hollow bones, pelvis, and spine or diffuse uptake in hollow bones with focal uptake in spinal lesions. 43 In another series, predominantly of patients with DLBCL, focal areas of increased FDG uptake anywhere in the bone marrow were considered representative of disease. PET could not detect the established BMI detected in the 4 cases with grade 1-2 follicular lymphoma. 41 More recently, El-Najjar et al., using a semi-quantitative analysis of PET images to assess BMI in FL, showed an improved sensitivity (58% vs. 31%) and specificity (96% vs. 92%) of detection when compared with visual inspection of the same images by the radiologist.
42
In a prospective analysis of 110 patients with newly diagnosed DLBCL, 21
patients had a BM biopsy with evidence of lymphoma, (7 concordant and 14 discordant). Six of the seven patients with concordant BMI also had abnormal PET uptake, defined as at least one focus of moderate or intense FDG uptake in a bone marrow territory using a three point system (1 low, 2 moderate, 3 high). Conversely, only 4 of 14 patients with discordant involvement were PET positive. These results suggest that PET can be helpful in predicting concordant BMI. It is less clear if PET has any utility in predicting discordant BMI. Unlike in previous studies, in this study there was no difference in survival between patients with concordant or discordant involvement, possibly in part due to the small sample size.
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A multinational study of 327 patients with DLBCL who underwent PET and BM biopsy at diagnosis, in which PET positivity was defined as focal bone marrow FDG uptake greater than liver uptake, revealed that only 10 of 241 patients with BM negativity by PET had BM biopsy positivity for lymphoma 45 . Two cases were discordant and 8 were concordant. Interestingly, 6 of the concordant cases demonstrated less than 10% tumor cells in the BM, presumably limiting detection on PET imaging. In a multivariate analysis, BMI detected by both PET and biopsy was associated with a significant decrease in OS. This effect was not seen with BMI detected either by BM biopsy or PET alone, suggesting that BMI identified by PET has independent prognostic value. Therefore, the authors hypothesize that PET scans, which preferentially detect concordant large cell BMI, are more specific indicators of poor prognosis disease in the marrow.
Finally, a meta-analysis of seven studies, including 654 patients with newly diagnosed DLBCL, showed that PET/CT had a pooled estimate of 88.7% sensitivity and 99.8% specificity. 46 This study further supports the view that a BM biopsy positive for lymphoma, whether concordant or discordant, does not change the management of a patient if the PET scan is interpreted as negative for BMI. It is important to note that the interpretation of the above studies is limited by the heterogeneity in criteria used for PET positivity of the bone marrow, with some using comparison to normal liver uptake and others using other subjective assessments.
Based on all the above and additional reports that support the role of PET-CT in the diagnosis of BMI, updated guidelines have recently been published by Cheson et al. 47-49 50 According to these recommendations a BM biopsy is no longer indicated for the routine staging of most DLBCL, if the PET-CT is negative for BMI. However, in 
Therapeutic Approach to Discordant Lymphomas:
There are no randomized trials or prospective studies addressing specific treatments for either nodal DLBCL with discordant indolent BMI or indolent nodal lymphomas with discordant aggressive lymphoma BMI. The majority of patients with DLBCL and discordant BMI with indolent lymphoma on biopsy are treated with anthracycline based regimens, such as R-CHOP. As referenced above, most retrospective analyses demonstrate that the presence of indolent BMI does not affect prognosis for patients treated with aggressive immunochemotherapy. If discordant aggressive lymphoma is found on BM biopsy of a patient with indolent nodal lymphoma, anthracycline-based treatment directed at the aggressive histology is typically used but again this has been poorly studied. While a majority of histologically discordant lymphomas in the BM are clonally related to the lymph node histology, a reasonable therapeutic approach is to target the aggressive histology, as described in retrospective series (figure 2).
1,2,4,5,19-22, 25 The role of upfront autologous stem cell transplant following first remission in transformed lymphomas has not been well established and there is no data assessing its role in discordant cases. 51, 52 An increased risk of central nervous system (CNS) involvement and CNS relapse in newly diagnosed patients with DLBCL who have concordant bone marrow 
Conclusions/Summary
In summary, concordant BMI with DLBCL portends a worse outcome and inferior overall survival compared to cases without BMI. In contrast, and importantly recognizing that this is a poorly studied area with a lack of large or prospective data, discordant BMI with an indolent B cell lymphoma in newly diagnosed DLBCL does not appear to impact negatively on prognosis. While FDG-PET is a helpful tool in the diagnosis of concordant marrow involvement in DLBCL, it is probably much less sensitive in detecting discordant BMI. Extrapolating from the limited number of studies that have looked at immunoglobulin gene rearrangements in these cases, a high proportion of histologically discordant lymphomas appear to be clonally related. 23 The molecular biology of discordance has been poorly studied and should be a focus of future studies in this area that aim at defining optimal approaches for these diseases. Approach to the diagnosis of discordant lymphoma. In the staging of DLBCL, a bone marrow biopsy should be preformed if there is increased PET-FCG uptake or for other clinical reasons such as the presence of cytopenias. If discordant indolent lymphoma is diagnosed in the bone marrow, clonality studies should be considered if available. In contrast to concordant bone marrow involvement in DLBCL, studies suggest that discordant involvement (with indolent disease in the bone marrow) is not associated with an increased risk of CNS disease.
